FINWIRES · TerminalLIVE
FINWIRES

CSPC Pharmaceutical Drug Shows 'Favorable' Anti-tumor Profile in Study

By

CSPC Pharmaceutical Group (HKG:1093) said currently available clinical data for its drug candidate SYS6043 indicates it could become a treatment option for multiple tumor types, according to a Tuesday filing with the Hong Kong bourse.

According to the company, the medicine demonstrated "favorable anti-tumor activity" in subjects enrolled in an open-label, phase 1/2 clinical study in China.

Among the 533 evaluable patients, the objective response rate was 41.8% while the median duration of response stood at 6.9 months. The disease control rate among the patients was assessed at 81.4%.

Based on the results, the firm said it would advance related studies of the drug in ovarian cancer, breast cancer, and small cell lung cancer.

Related Articles

Asia

Market Chatter: Regional Japanese Banks Retreat from China as Costs Rise and Client Needs Shift

Rising labor costs and softening demand from Japanese manufacturers are driving Japan's regional banks to shift from China to Southeast Asia and India, creating hurdles for suppliers tied to the Chinese market, Nikkei Asia reported Wednesday.According to Nikkei's analysis of 61 regional lenders, China's share of overseas offices fell from 50 in April 2021 to just 40 by the end of March, despite still representing nearly half of all foreign locations.Hokkaido Bank shuttered its Shenyang outpost in May 2025 after nearly two decades, relocating operations back to Japan, while Bank of Kyoto closed its Dalian office last year and merged functions into its Shanghai branch, the news agency said.Citing mounting maintenance burdens and declining customer demand, the Bank of Kyoto noted that downsizing became the logical response to falling client needs, the publication said.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

$^N225
Asia

Market Chatter: Jardine Matheson Eyes AU$1.5 Billion Loan to Finance I-Med Purchase

Jardine Matheson (SGX:J36) is looking to secure a five-year loan of about AU$1.5 billion to finance the takeover of I-Med Radiology Network, an Australian medical diagnostic imaging provider, Bloomberg News reported on Wednesday, citing people familiar with the matter.The loan could carry an interest margin of around a 100 basis points range over the benchmark Bank Bill Swap Yield, the people told the news outlet. However, the loan discussions are still in the early stages and details could still change, according to the people.A Jardine representative declined to comment, Bloomberg said.The Singapore-listed conglomerate agreed to acquire I-Med for AU$3.4 billion from private equity firm Permira. Under the deal, Jardine will also acquire a minority stake in radiology AI solutions firm, Harrison.ai, the report added.I-Med owns more than 250 clinics across Australia and was acquired by Permira from EQT AB for around $1.3 billion in 2018, the report noted.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

$SGX:J36
Asia

Qantas Airways Project Sunrise Completes Maiden Test Flight Ahead of Non-Stop London, New York Services

Qantas Airways (ASX:QAN) said its Project Sunrise Airbus A350-1000ULR has completed its maiden test flight ahead of the launch of commercial flights connecting Australia's east coast to London and New York non-stop for the first time, according to a Wednesday statement.The airline said the flight tested the aircraft's primary systems, including its specialized fuel system that will enable commercial flights of up to 22 hours non-stop, marking the beginning of a two-month testing campaign.A second Project Sunrise aircraft is progressing through Airbus' final assembly line with delivery to Qantas expected in April 2027, the statement added.Qantas will disclose the first Project Sunrise route and timing of its inaugural commercial services later in June, it added.

$ASX:QAN